Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer 2026 CMS Physician Fee Schedule Final Rule provides a 300% per-f

Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (February 12, 2026) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly

effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions,

announces financial results for the three and twelve months ended December 31, 2025.

include the following:

the publication of Current Procedural Terminology (CPT) codes for treating non-melanoma skin cancer with SRT in November

- with a per-fraction increase of more than 300% versus prior delivery code - and despite a very tight

subsequent selling window in the midst of multiple holidays, we shipped 14 systems in Q4 without any contribution from our

historically largest customer, compared with six units in Q3 excluding shipments to that customer," said Joe Sardano,

Chairman and Chief Executive Officer of Sensus Healthcare. "With dedicated reimbursement codes now in place, a strong

balance sheet with no debt and significantly enhanced physician economics, we look forward to 2026 with greater business

control, predictability, and optimism."

utilization increased significantly in 2025, with treatments up more than eight-fold versus 2024 and the number of patients treated

up by more than 250%. In several cases, the new reimbursement rates served as catalysts for system purchases by FDA customers,"

he added. "International demand contributed meaningfully to the fourth quarter with shipments to China, and international

markets remain an important component of our growth strategy."

to the first quarter of 2026, based on our current pipeline and order activity we expect shipments to exceed fourth quarter 2025

levels without any contribution from our historically largest customer. More broadly, 2026 represents a new operating environment

for Sensus, one we intend to fully leverage including by hiring several new sales reps," Sardano continued. "With

attractive reimbursement, a more diversified customer base, new international opportunities and a continued commitment to tight

expense management, our objective is to achieve full-year profitability."

Quarter Financial Results

for the fourth quarter of 2025 were $4.9 million, compared with $13.1 million for the fourth quarter of 2024. The decrease was

primarily driven by a lower number of units sold, reflecting reduced sales to our largest customer, slightly offset by revenue

recognized from the new placements under the FDA program.

of sales for the fourth quarter of 2025 was $3.0 million, compared with $6.0 million in the prior-year quarter. The decrease was

primarily related to a lower number of units sold, offset by higher cost of service and costs associated with the new placements

under the FDA program.

profit for the fourth quarter of 2025 was $1.9 million, or 38.8% of revenues, compared with $7.1 million, or 54.2% of revenues,

for the fourth quarter of 2024. The decrease was primarily driven by lower sales, higher costs of servicing systems and the costs

associated with the new placement program.

and administrative expenses were $1.8 million for the fourth quarter of 2025, compared with $2.4 million in the prior-year quarter.

The decrease was primarily due to lower professional fees and compensation costs.

and marketing expenses were $1.4 million for the fourth quarter of 2025, remaining consistent with the prior-year quarter.

and development expenses were $1.9 million for the fourth quarter of 2025, compared with $1.6 million for the prior-year quarter.

The increase was primarily due to an increase in product development costs related to next-generation systems.

income, net of $0.2 million remained consistent with the prior-year quarter.

loss for the fourth quarter of 2025 was $3.2 million, or $0.19 per share, compared with net income of $1.5 million, or $0.09 per

diluted share, for the fourth quarter of 2024.

EBITDA for the fourth quarter of 2025 was negative $3.0 million, compared with $1.9 million for the fourth quarter of 2024. Adjusted

EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation

expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reason these non-GAAP financial

measures are provided.

and cash equivalents were $22.1 million as of December 31, 2025, unchanged from December 31, 2024. The Company had no outstanding

borrowings under its revolving line of credit at either year-end. Prepaid inventory was $1.5 million as of December 31, 2025,

compared with $3.3 million as of December 31, 2024. Inventories were $14.6 million as of December 31, 2025, compared with $10.1

million as of December 31, 2024.

Year Financial Results

for 2025 were $27.5 million, compared with $41.8 million in 2024. The decrease in revenue was primarily driven by a lower number

of units sold, reflecting reduced sales to our largest customer, slightly offset by revenue recognized from the new placements

under the FDA program.

of sales for 2025 was $15.6 million, compared with $17.4 million in 2024. The decrease was primarily related to a lower number

of units sold offset by significantly higher cost of service and costs associated with the new placements under the FDA program.

profit for 2025 was $11.9 million, or 43.3% of revenue, compared with $24.4 million, or 58.4% of revenue, in 2024. The decrease

was primarily driven by lower sales, higher costs of servicing systems and the cost associated with the new placement program.

and administrative expenses for 2025 were $7.9 million, compared with $7.1 million in 2024. The increase was primarily due to

higher professional fees, insurance costs and compensation costs.

and marketing expenses for 2025 were $6.5 million, compared with $5.0 million in 2024. The increase was primarily driven by higher

tradeshow costs and, payroll cost due to an increase in headcount.

and development expenses for 2025 were $7.8 million, compared with $4.2 million in 2024. The increase was primarily due to significant

lobbying costs related to billing code reimbursement, increased headcount and an increase in product development costs related

to next-generation systems.

income, net of $0.7 million and $0.9 million in the years ended December 31, 2025 and 2024, respectively, relates primarily to

loss for 2025 was $7.7 million, or $0.47 per share, compared with net income of $6.6 million, or $0.41 per diluted share, for

EBITDA for 2025 was negative $9.6 million, compared with $8.7 million for 2024.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure,

in its analysis of the Company's performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures,

nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation

of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense,

provides useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare.

Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from

those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists

investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure

underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the

TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management

will discuss these financial results, provide a business update and answer questions.

are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the

live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register

can access the conference call by dialing 844-481-2811 (U.S. and Canada) or 412-317-0676 (International). Please ask the operator

to be connected to the Sensus Healthcare conference call.

call will be webcast live and can be accessed at this link, which is also in the Investor Relations section of the Company's

website at www.sensushealthcare.com.

the conclusion of the conference call, a telephone replay will be available until March 12, 2026, by dialing 855-669-9658 (U.S.

and Canada) or 412-317-0088 (International). At the system prompt, enter the replay code 1795391. An archived webcast will be

available in the Investor Relations section of the Company's website for a period of time.

Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging

its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly

effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare

offers solutions that are safe, precise and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

press release includes statements that are, or may be deemed, forward-looking statements.'' In some

cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates,"

"anticipates," "expects," "plans," "intends," "may," "could,"

"might," "will," "should," "approximately," "potential" or negative

or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus,